Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged to match a person’s genetic makeup or a tumor’s genetic profile. As a result, patients with lung cancer now typically receive molecular testing that guides their physicians in determining which therapies are more likely to boost the chances of survival while limiting the potential for adverse effects. Results from studies evaluating ALK-inhibitors continue to show efficacy and initial studies exploring immunomodulatory approaches using anti-PD-1 and anti-PD-L1 antibodies have demonstrated promising results in lung cancer. The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.
CancerConnect News coverage of advances in the management of lung cancer included the following key developments:
Lung Cancer Screening
2015 FDA News
More NSCLC News
LEARNING MORE ABOUT LUNG CANCER
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey?
- Sign up for monthly newsletters on lung cancer here.
- Get the facts about lung cancer here.
- Join ongoing discussions with other individuals affected by lung cancer in the CancerConnect private online support group here.
- Follow CancerConnect on Facebook and Twitter.
Copyright © 2018 CancerConnect. All Rights Reserved.